22 PBAC submissions on file, active 2005–2025. 68% have been recommended.
Submissions
22
2005 → 2025
Win rate
68 %
15 recommended of 22 bucketable
Drugs
7 · 5 listed
unique molecules submitted
PBS spend captured
$285M
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
1×claim of superior safety over insulin glargine not adequately justified
1×modelling approach not appropriate with results mainly driven by assumed differences in self-monitoring of blood glucose (SMBG) testing rather than trial-based differences
1×one-year time horizon inappropriate for chronic disease
1×utilities derived from mapping SF-36 to EQ-5D rather than SF-6D
1×differences in quality of life not adequately supported by trial results